The DOI matches its Crossref record; 162 of the 162 references it cites were found in a registry or an index.
Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis
Open accessAbstract
The metabolic functions of androgen receptor (AR) in normal prostate are circumvented in prostate cancer (PCa) to drive tumor growth, and the AR also can acquire new growth-promoting functions during PCa development and progression through genetic and epigenetic mechanisms. Androgen deprivation therapy (ADT, surgical or medical castration) is the standard treatment for metastatic PCa, but patients invariably relapse despite castrate androgen levels (castration-resistant PCa, CRPC). Early studies from many groups had shown that AR was highly expressed and transcriptionally active in CRPC, and indicated that steroids from the adrenal glands were contributing to this AR activity. More recent studies showed that CRPC cells had increased expression of enzymes mediating androgen synthesis from adrenal steroids, and could synthesize androgens de novo from cholesterol. Phase III clinical trials showing a survival advantage in CRPC for treatment with abiraterone (inhibitor of the enzyme CYP17A1 required for androgen synthesis that markedly reduces androgens and precursor steroids) and for enzalutamide (new AR antagonist) have now confirmed that AR activity driven by residual androgens makes a major contribution to CRPC, and led to the recent Food and Drug Administration approval of both agents. Unfortunately, patients treated with these agents for advanced CRPC generally relapse within a year and AR appears to be active in the relapsed tumors, but the molecular mechanisms mediating intrinsic or acquired resistance to these AR-targeted therapies remain to be defined. This review outlines AR functions that contribute to PCa development and progression, the roles of intratumoral androgen synthesis and AR structural alterations in driving AR activity in CRPC, mechanisms of action for abiraterone and enzalutamide, and possible mechanisms of resistance to these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. A., & Shi, Y. (2004) · Cell · doi:10.1016/j.cell.2004.12.012 · Cited by 4,051
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription
Metzger, E., Wissmann, M., Yin, N., Müller, J. M., Schneider, R., Peters, A. H. F. M., Günther, T., Buettner, R., & Schüle, R. (2005) · Nature · doi:10.1038/nature04020 · Cited by 1,733
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Self-citationCarver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Self-citationHu, R., Dunn, T. A., Wei, S., Isharwal, S., Veltri, R. W., Humphreys, E., Han, M., Partin, A. W., Vessella, R. L., Isaacs, W. B., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2764 · Cited by 1,077
FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription
Lupien, M., Eeckhoute, J., Meyer, C. A., Wang, Q., Zhang, Y., Li, W., Carroll, J. S., Liu, X. S., & Brown, M. (2008) · Cell · doi:10.1016/j.cell.2008.01.018 · Cited by 983
Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkmann, A. O., & Mulder, E. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80067-1 · Cited by 950
Integrative molecular concept modeling of prostate cancer progression
Tomlins, S. A., Mehra, R., Rhodes, D. R., Cao, X., Wang, L., Dhanasekaran, S. M., Kalyana-Sundaram, S., Wei, J. T., Rubin, M. A., Pienta, K. J., et al. (2007) · Nature Genetics · doi:10.1038/ng1935 · Cited by 922
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 902
Self-citationGuo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
Xu, K., Wu, Z. J., Groner, A. C., He, H. H., Cai, C., Lis, R. T., Wu, X., Stack, E. C., Loda, M., Liu, T., et al. (2012) · Science · doi:10.1126/science.1227604 · Cited by 875
Self-citationBilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391504 · Cited by 859
Yu, J., Yu, J., Mani, R.-S., Cao, Q., Brenner, C. J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.018 · Cited by 850
Yamane, K., Toumazou, C., Tsukada, Y.-I., Erdjument-Bromage, H., Tempst, P., Wong, J., & Zhang, Y. (2006) · Cell · doi:10.1016/j.cell.2006.03.027 · Cited by 837
Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L., & Tindall, D. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0594 · Cited by 834
Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748
Locke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., Ettinger, S. L., Gleave, M. E., & Nelson, C. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5997 · Cited by 747
Thalmann, G. N., Anezinis, P., Chang, S., Zhau, H. E., Kim, E. E., Hopwood, V. L., Pathak, S., von Eschenbach, A. C., & Chung, L. W. K. (1994) · PubMed · Cited by 727
Gregory, C. W., He, B., Johnson, R. T., Ford, O. H., Mohler, J. L., French, F. S., & Wilson, E. M. (2001) · PubMed · Cited by 708
Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer
Tomlins, S. A., Laxman, B., Varambally, S., Cao, X., Yu, J., Helgeson, B. E., Cao, Q., Prensner, J. R., Rubin, M. A., Shah, R. B., et al. (2008) · Neoplasia · doi:10.1593/neo.07822 · Cited by 690
Li, Y., Chan, S. C., Brand, L. J., Hwang, T. H., Silverstein, K. A. T., & Dehm, S. M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3630 · Cited by 680
The Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675
Formation of the Androgen Receptor Transcription Complex
Shang, Y., Myers, M., & Brown, M. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00471-9 · Cited by 672
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., Chen, Y., Grillot, K., Bischoff, E. D., Cai, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3948 · Cited by 662
Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., & Sawyers, C. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012443107 · Cited by 639
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
Massie, C. E., Lynch, A., Ramos‐Montoya, A., Boren, J., Stark, R., Fazli, L., Warren, A., Scott, H., Madhu, B., Sharma, N., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.158 · Cited by 624
Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor
Matias, P. M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, P., Wegg, A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004571200 · Cited by 608
Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression
Wissmann, M., Yin, N., Müller, J. M., Greschik, H., Fodor, B. D., Jenuwein, T., Vogler, C., Schneider, R., Günther, T., Buettner, R., et al. (2007) · Nature Cell Biology · doi:10.1038/ncb1546 · Cited by 598
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Taplin, M., Bubley, G. J., Ko, Y., Small, E. J., Upton, M. P., Rajeshkumar, B. R., & Balk, S. P. (1999) · PubMed · Cited by 596
Self-citationMostaghel, E. A., Marck, B. T., Plymate, S. R., Vessella, R. L., Balk, S., Matsumoto, A. M., Nelson, P. S., & Montgomery, R. B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0728 · Cited by 588
Self-citationHu, R., Lu, C., Mostaghel, E. A., Yegnasubramanian, S., Gurel, M., Tannahill, C., Edwards, J., Isaacs, W. B., Nelson, P. S., Bluemn, E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3892 · Cited by 583
Opposing LSD1 complexes function in developmental gene activation and repression programmes
Wang, J., Scully, K., Zhu, X., Cai, L., Zhang, J., Prefontaine, G. G., Krones, A., Ohgi, K. A., Zhu, P., Garcia-Bassets, I., et al. (2007) · Nature · doi:10.1038/nature05671 · Cited by 579
Holzbeierlein, J., Lal, P., LaTulippe, E., Smith, A., Satagopan, J., Zhang, L., Ryan, C., Smith, S., Scher, H., Scardino, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63112-4 · Cited by 577
Zhao, X.-Y., Malloy, P. J., Krishnan, A. V., Swami, S., Navone, N. M., Peehl, D. M., & Feldman, D. (2000) · Nature Medicine · doi:10.1038/76287 · Cited by 536
Mostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
DNA Oxidation as Triggered by H3K9me2 Demethylation Drives Estrogen-Induced Gene Expression
Perillo, B., Ombra, M. N., Bertoni, A., Cuozzo, C., Sacchetti, S., Sasso, A., Chiariotti, L., Malorni, A., Abbondanza, C., & Avvedimento, E. V. (2008) · Science · doi:10.1126/science.1147674 · Cited by 527
Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth
Mulholland, D. J., Tran, L. M., Li, Y., Cai, H., Morim, A., Wang, S., Plaisier, S., Garraway, I. P., Huang, J., Graeber, T. G., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.006 · Cited by 516
Small, E. J., Halabi, S., Dawson, N. A., Stadler, W. M., Rini, B. I., Picus, J., Gable, P., Torti, F. M., Kaplan, E., & Vogelzang, N. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.037 · Cited by 504
Andersen, R. J., Mawji, N. R., Wang, J., Wang, G., Haile, S., Myung, J.-K., Watt, K., Tam, T., Yang, Y. C., Bañuelos, C. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.027 · Cited by 503
Sack, J. S., Kish, K. F., Wang, C., Attar, R. M., Kiefer, S. E., An, Y., Wu, G. Y., Scheffler, J. E., Salvati, M. E., Krystek, S. R., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081565498 · Cited by 491
Testosterone and Dihydrotestosterone Tissue Levels in Recurrent Prostate Cancer
Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B., & Mohler, J. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0525 · Cited by 488
Nucleosome dynamics define transcriptional enhancers
He, H. H., Meyer, C. A., Shin, H., Bailey, S. T., Wei, G., Wang, Q., Zhang, Y., Xu, K., Ni, M., Lupien, M., et al. (2010) · Nature Genetics · doi:10.1038/ng.545 · Cited by 475
Cai, C., He, H. H., Chen, S., Coleman, I., Wang, H., Fang, Z., Chen, S., Nelson, P. S., Liu, X. S., Brown, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.001 · Cited by 454
Self-citationLin, H.-K. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf406 · Cited by 450
Culig, Z. (1993) · Molecular Endocrinology · doi:10.1210/me.7.12.1541 · Cited by 440
Garcia-Bassets, I., Kwon, Y.-S., Telese, F., Prefontaine, G. G., Hutt, K. R., Cheng, C. S., Ju, B.-G., Ohgi, K. A., Wang, J., Escoubet-Lozach, L., et al. (2007) · Cell · doi:10.1016/j.cell.2006.12.038 · Cited by 437
Cai, C., Chen, S., Ng, P., Bubley, G. J., Nelson, P. S., Mostaghel, E. A., Marck, B., Matsumoto, A. M., Simon, N. I., Wang, H., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0532 · Cited by 433
Self-citationStructural basis for antagonism and resistance of bicalutamide in prostate cancer
Bohl, C. E., Gao, W., Miller, D. D., Bell, C. E., & Dalton, J. T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500381102 · Cited by 421
Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor.
Lin, H.-K., Yeh, S., Kang, H.-Y., & Chang, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121173298 · Cited by 401
Zegarra-Moro, O. L., Schmidt, L. J., Huang, H., & Tindall, D. J. (2002) · PubMed · Cited by 399
Alternatively spliced androgen receptor variants
Dehm, S. M., & Tindall, D. J. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0141 · Cited by 380
Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.021 · Cited by 364
Taplin, M.-E., Rajeshkumar, B., Halabi, S., Werner, C. P., Woda, B. A., Picus, J., Stadler, W., Hayes, D. F., Kantoff, P. W., Vogelzang, N. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.102 · Cited by 364
Beta-catenin affects androgen receptor transcriptional activity and ligand specificity.
Truica, C. I., Byers, S. W., & Gelmann, E. P. (2000) · PubMed · Cited by 350
Linking β-Catenin to Androgen-signaling Pathway
Yang, F., Li, X., Sharma, M., Sasaki, C. Y., Longo, D. L., Lim, B., & Sun, Z. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111962200 · Cited by 342
AR, the cell cycle, and prostate cancer
Balk, S. P., & Knudsen, K. E. (2008) · Nuclear Receptor Signaling · doi:10.1621/nrs.06001 · Cited by 333
Self-citationSharma, A., Yeow, W.-S., Ertel, A., Coleman, I., Clegg, N., Thangavel, C., Morrissey, C., Zhang, X., Comstock, C. E. S., Witkiewicz, A. K., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci44239 · Cited by 331
(1994) · PubMed Central · Cited by 328
Acevedo, V. D., Gangula, R. D., Freeman, K. W., Li, R., Zhang, Y., Wang, F., Ayala, G. E., Peterson, L. E., Ittmann, M., & Spencer, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.11.004 · Cited by 308
Phosphorylation of histone H3T6 by PKCβI controls demethylation at histone H3K4
Metzger, E., Imhof, A., Patel, D., Kahl, P., Hoffmeyer, K., Friedrichs, N., Müller, J. M., Greschik, H., Kirfel, J., Ji, S., et al. (2010) · Nature · doi:10.1038/nature08839 · Cited by 304
Xu, Y., Chen, S.-Y., Ross, K. N., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4472 · Cited by 301
Self-citationHe, B., Gampe, R. T., Kole, A. J., Hnat, A. T., Stanley, T. B., An, G., Stewart, E. L., Kalman, R. I., Minges, J. T., & Wilson, E. M. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.09.036 · Cited by 295
Heparin-binding keratinocyte growth factor is a candidate stromal-to- epithelial-cell andromedin
Yan, G. (1992) · Molecular Endocrinology · doi:10.1210/me.6.12.2123 · Cited by 294
Ettinger, S. L., Sobel, R., Whitmore, T. G., Akbari, M., Bradley, D. R., Gleave, M. E., & Nelson, C. C. (2004) · Cancer Research · doi:10.1158/0008-5472.can-2148-2 · Cited by 287
Gregory, C. W., Hamil, K. G., Kim, D., Hall, S. H., Pretlow, T. G., Mohler, J. L., & French, F. S. (1998) · PubMed · Cited by 275
Mahajan, N. P., Liu, Y., Majumder, S., Warren, M. R., Parker, C. E., Mohler, J. L., Earp, H. S., & Whang, Y. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700420104 · Cited by 274
ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer
Cai, C., Wang, H., He, H. H., Chen, S., He, L., Ma, F., Mucci, L., Wang, Q., Fiore, C., Sowalsky, A. G., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66666 · Cited by 273
Self-citationHu, Q., Kwon, Y.-S., Nunez, E., Cardamone, M. D., Hutt, K. R., Ohgi, K. A., Garcia-Bassets, I., Rose, D. W., Glass, C. K., Rosenfeld, M. G., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810634105 · Cited by 264
Kumar, A., White, T. A., MacKenzie, A. P., Clegg, N., Lee, C., Dumpit, R. F., Coleman, I., Ng, S. B., Salipante, S. J., Rieder, M. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108745108 · Cited by 263
Samson, D. J., Seidenfeld, J., Schmitt, B., Hasselblad, V., Albertsen, P. C., Bennett, C. L., Wilt, T. J., & Aronson, N. (2002) · Cancer · doi:10.1002/cncr.10647 · Cited by 259
Zhu, P., Baek, S. H., Bourk, E. M., Ohgi, K. A., Garcia-Bassets, I., Sanjo, H., Akira, S., Kotol, P. F., Glass, C. K., Rosenfeld, M. G., et al. (2006) · Cell · doi:10.1016/j.cell.2005.12.032 · Cited by 259
Xu, K., Shimelis, H., Linn, D. E., Jiang, R., Yang, X., Sun, F., Guo, Z., Chen, H., Li, W., Chen, H., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.021 · Cited by 248
Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
Zhang, X., Morrissey, C., Sun, S., Ketchandji, M., Nelson, P. S., True, L. D., Vakar-Lopez, F., Vessella, R. L., & Plymate, S. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027970 · Cited by 240
Masiello, D., Cheng, S., Bubley, G. J., Lu, M. L., & Balk, S. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203310200 · Cited by 240
Self-citationRecognition and Accommodation at the Androgen Receptor Coactivator Binding Interface
Hur, E., Pfaff, S. J., Payne, E. S., Grøn, H., Buehrer, B. M., & Fletterick, R. J. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020274 · Cited by 234
Persistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men
Page, S. T., Lin, D. W., Mostaghel, E. A., Hess, D. L., True, L. D., Amory, J. K., Nelson, P. S., Matsumoto, A. M., & Bremner, W. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0968 · Cited by 229
Metzger, E., Yin, N., Wissmann, M., Kunowska, N., Fischer, K., Friedrichs, N., Patnaik, D., Higgins, J. M. G., Potier, N., Scheidtmann, K.-H., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1668 · Cited by 228
Dillard, P. R., Lin, M.-F., & Khan, S. A. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.013 · Cited by 225
Nishiyama, T., Hashimoto, Y., & Takahashi, K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0913 · Cited by 223
Chan, S. C., Li, Y., & Dehm, S. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.352930 · Cited by 218
Bélanger, B., Bélanger, A., Labrie, F., Dupont, A., Cusan, L., & Monfette, G. (1989) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(89)90514-1 · Cited by 212
Schaufele, F., Carbonell, X., Guerbadot, M., Borngraeber, S., Chapman, M. S., Ma, A. A. K., Miner, J. N., & Diamond, M. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408819102 · Cited by 208
Knudsen, K. E., Arden, K. C., & Cavenee, W. K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20213 · Cited by 204
Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1
Chen, S., Xu, Y., Yuan, X., Bubley, G. J., & Balk, S. P. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604193103 · Cited by 204
Self-citationVerras, M., Lee, J., Xue, H., Li, T.-H., Wang, Y., & Sun, Z. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3552 · Cited by 203
Li, Y., Hwang, T. H., Oseth, L. A., Hauge, A., Vessella, R. L., Schmechel, S. C., Hirsch, B., Beckman, K. B., Silverstein, K. A., & Dehm, S. M. (2012) · Oncogene · doi:10.1038/onc.2011.637 · Cited by 202
Role of SRC-1 in the Promotion of Prostate Cancer Cell Growth and Tumor Progression
Agoulnik, I. U., Vaid, A., Bingman, W. E., Erdeme, H., Frolov, A., Smith, C. L., Ayala, G., Ittmann, M. M., & Weigel, N. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3541 · Cited by 202
Epidermal Growth Factor Increases Coactivation of the Androgen Receptor in Recurrent Prostate Cancer
Gregory, C. W., Fei, X., Ponguta, L. A., He, B., Bill, H. M., French, F. S., & Wilson, E. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307649200 · Cited by 201
Kang, Z., Jänne, O. A., & Palvimo, J. J. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0245 · Cited by 193
Lin, H.-K., Hu, Y.-C., Yang, L., Altuwaijri, S., Chen, Y.-T., Kang, H.-Y., & Chang, C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300676200 · Cited by 186
Lu, S., Liu, M., Epner, D. E., Tsai, M., & Tsai, M. (1999) · Molecular Endocrinology · doi:10.1210/me.13.3.376 · Cited by 185
Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy
Cai, C., & Balk, S. P. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0339 · Cited by 177
Self-citationEvidence of limited contributions for intratumoral steroidogenesis in prostate cancer
Hofland, J., van Weerden, W. M., Dits, N. F. J., Steenbergen, J., van Leenders, G. J. L. H., Jenster, G., Schröder, F. H., & de Jong, F. H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2092 · Cited by 176
Stress Kinase Signaling Regulates Androgen Receptor Phosphorylation, Transcription, and Localization
Gioeli, D., Black, B. E., Gordon, V., Spencer, A., Kesler, C. T., Eblen, S. T., Paschal, B. M., & Weber, M. J. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0351 · Cited by 175
Mizokami, A., Koh, E., Fujita, H., Maeda, Y., Egawa, M., Koshida, K., Honma, S., Keller, E. T., & Namiki, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0130 · Cited by 175
Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation
Gaughan, L. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki141 · Cited by 174
Schaeffer, E. M., Marchionni, L., Huang, Z., Simons, B., Blackman, A., Yu, W., Parmigiani, G., & Berman, D. M. (2008) · Oncogene · doi:10.1038/onc.2008.327 · Cited by 172
Compartmentalization of androgen receptor protein–protein interactions in living cells
van Royen, M. E., Cunha, S. M., Brink, M. C., Mattern, K. A., Nigg, A. L., Dubbink, H. J., Verschure, P. J., Trapman, J., & Houtsmuller, A. B. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200609178 · Cited by 170
Cai, C., Wang, H., Xu, Y., Chen, S., & Balk, S. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0395 · Cited by 169
Self-citationAgoulnik, I. U., Vaid, A., Nakka, M., Alvarado, M., Bingman, W. E., Erdem, H., Frolov, A., Smith, C. L., Ayala, G. E., Ittmann, M. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1023 · Cited by 168
Post-translational modification of the androgen receptor
Gioeli, D. G., & Paschal, B. M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.004 · Cited by 164
SOX9 Is Expressed in Human Fetal Prostate Epithelium and Enhances Prostate Cancer Invasion
Wang, H., Leav, I., Ibaragi, S., Wegner, M., Hu, G.-F., Lu, M. L., Balk, S. P., & Yuan, X. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5915 · Cited by 163
Self-citationA transcriptional repressor co‐regulatory network governing androgen response in prostate cancers
Chng, K. R., Chang, C. W., Tan, S. K., Yang, C., Hong, S. Z., Sng, N. Y. W., & Cheung, E. C. W. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.112 · Cited by 159
Hodgson, M. C., Astapova, I. I., Cheng, S., Lee, L. J., Verhoeven, M. C., Choi, E., Balk, S. P., & Hollenberg, A. N. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408972200 · Cited by 158
Self-citationCDK9 Regulates AR Promoter Selectivity and Cell Growth through Serine 81 Phosphorylation
Gordon, V. L., Bhadel, S., Wunderlich, W., Zhang, J., Ficarro, S. B., Mollah, S., Shabanowitz, J., Hunt, D. F., Xénarios, I., Hahn, W. C., et al. (2010) · Molecular Endocrinology · doi:10.1210/me.2010-0238 · Cited by 152
Ligand-dependent inhibition of β-catenin/TCF signaling by androgen receptor
Chesire, D. R., & Isaacs, W. B. (2002) · Oncogene · doi:10.1038/sj.onc.1206049 · Cited by 151
Stepwise androgen receptor dimerization
van Royen, M. E., van Cappellen, W. A., de Vos, C., Houtsmuller, A. B., & Trapman, J. (2012) · Journal of Cell Science · doi:10.1242/jcs.096792 · Cited by 143
Wang, H., McKnight, N. C., Zhang, T., Lu, M. L., Balk, S. P., & Yuan, X. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1672 · Cited by 143
Self-citationLigand-Specific Dynamics of the Androgen Receptor at Its Response Element in Living Cells
Klokk, T. I., Kurys, P., Elbi, C., Nagaich, A. K., Hendarwanto, A., Slagsvold, T., Chang, C., Hager, G. L., & Saatcioglu, F. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01297-06 · Cited by 142
Hey1, a Mediator of Notch Signaling, Is an Androgen Receptor Corepressor
Belandia, B., Powell, S. M., Garcia-Pedrero, J. M., Walker, M. M., Bevan, C. L., & Parker, M. G. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.4.1425-1436.2005 · Cited by 137
Cooperation between Polycomb and androgen receptor during oncogenic transformation.Preprint
Zhao, J. C., Yu, J.-J., Runkle, C., Wu, L.-T., Hu, M., Wu, D.-Y., Liu, J., Wang, Q.-B., Qin, Z., & Yu, J.-D. (2012) · Genome Research · doi:10.1101/gr.131508.111 · Cited by 134
Genomic Strategy for Targeting Therapy in Castration-Resistant Prostate Cancer
Mendiratta, P., Mostaghel, E. A., Guinney, J., Tewari, A. K., Porrello, A., Barry, W. T., Nelson, P. S., & Febbo, P. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2882 · Cited by 134
Regulation of the androgen receptor by SET9-mediated methylation.
Gaughan, L., Stockley, J., Wang, N., McCracken, S. R. C., Treumann, A., Armstrong, K., Shaheen, F., Watt, K., McEwan, I. J., Wang, C., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq861 · Cited by 127
Thomsen, M. K., Ambroisine, L., Wynn, S. L., Cheah, K. S. E., Foster, C. S., Fisher, G., Berney, D. M., Møller, H., Reuter, V. E., Scardino, P. T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2370 · Cited by 126
Bohl, C. E., Wu, Z. R., Miller, D. D., Bell, C. E., & Dalton, J. T. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611711200 · Cited by 124
Song, L., Coghlan, M., & Gelmann, E. P. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0189 · Cited by 124
SRY Interacts with and Negatively Regulates Androgen Receptor Transcriptional Activity
Yuan, X., Lu, M. L., Li, T., & Balk, S. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108404200 · Cited by 121
Self-citationInhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor.
Cheng, S., Brzostek, S., Lee, S. R., Hollenberg, A. N., & Balk, S. P. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.7.0870 · Cited by 121
Self-citationYoon, H.-G., & Wong, J. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0324 · Cited by 120
Chen, S., Gulla, S., Cai, C., & Balk, S. P. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.325290 · Cited by 119
Self-citationKraus, S., Gioeli, D., Vomastek, T., Gordon, V., & Weber, M. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0596 · Cited by 118
Trans-repression of β-Catenin Activity by Nuclear Receptors
Shah, S., Hecht, A., Pestell, R. G., & Byers, S. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307154200 · Cited by 116
Antiandrogens prevent stable DNA-binding of the androgen receptor
Farla, P., Hersmus, R., Trapman, J., & Houtsmuller, A. B. (2005) · Journal of Cell Science · doi:10.1242/jcs.02546 · Cited by 114
Targeting CYP17: established and novel approaches in prostate cancer
Yap, T. A., Carden, C. P., Attard, G., & Bono, J. S. D. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.004 · Cited by 110
Mulholland, D. J., Read, J. T., Rennie, P. S., Cox, M., & Nelson, C. C. (2003) · Oncogene · doi:10.1038/sj.onc.1206802 · Cited by 104
Inhibition of Androgen Receptor-Mediated Transcription by Amino-Terminal Enhancer of split
Yu, X., Li, P., Roeder, R. G., & Wang, Z. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.14.4614-4625.2001 · Cited by 104
Prohibitin, a protein downregulated by androgens, represses androgen receptor activity
Gamble, S. C., Chotai, D., Odontiadis, M., Dart, D. A., Brooke, G. N., Powell, S. M., Reebye, V., Varela‐Carver, A., Kawano, Y., Waxman, J., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209967 · Cited by 103
Lysine Methylation and Functional Modulation of Androgen Receptor by Set9 Methyltransferase
Ko, S., Ahn, J., Song, C. S., Kim, S.-Y., Knapczyk‐Stwora, K., & Chatterjee, B. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0482 · Cited by 102
Sox9 is required for prostate development
Thomsen, M. K., Butler, C. M., Shen, M. M., & Swain, A. (2008) · Developmental Biology · doi:10.1016/j.ydbio.2008.01.030 · Cited by 100
Cell-specific Regulation of Androgen Receptor Phosphorylation in Vivo
Taneja, S. S., Ha, S., Swenson, N. K., Huang, H. Y., Lee, P., Melamed, J., Shapiro, E., Garabedian, M. J., & Logan, S. K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508442200 · Cited by 100
Geller, J., Albert, J. D., Nachtsheim, D. A., & Loza, D. (1984) · Journal of Urology · doi:10.1016/s0022-5347(17)49829-6 · Cited by 98
Hodgson, M. C., Astapova, I. I., Hollenberg, A. N., & Balk, S. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0617 · Cited by 92
Self-citationCurtin, D., Jenkins, S. C., Farmer, N., Anderson, A. C., Haisenleder, D. J., Rissman, E. F., Wilson, E. M., & Shupnik, M. A. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.11.0723 · Cited by 86
Taplin, M., Regan, M. M., Ko, Y., Bubley, G. J., Duggan, S., Werner, L. L., Beer, T. M., Ryan, C. W., Mathew, P. F., Tu, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1722 · Cited by 86
Self-citationChen, S., Kesler, C. T., Paschal, B. M., & Balk, S. P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.043133 · Cited by 80
Self-citationYuan, X., Li, T., Wang, H., Zhang, T., Barua, M., Borgesi, R. A., Bubley, G. J., Lu, M. L., & Balk, S. P. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051047 · Cited by 75
Self-citationPhosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer
Ha, S., Iqbal, N. J., Mita, P., Ruoff, R., Gerald, W. L., Lepor, H., Taneja, S. S., Lee, P., Melamed, J., Garabedian, M. J., et al. (2012) · Oncogene · doi:10.1038/onc.2012.412 · Cited by 74
Chen, S., Wulf, G. M., Zhou, X. Z., Rubin, M. A., Lu, K. P., & Balk, S. P. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.3.929-939.2006 · Cited by 74
Self-citationGeller, J. (1985) · PubMed · Cited by 74
Fang, Z., Zhang, T., Dizeyi, N., Chen, S., Wang, H., Swanson, K. D., Cai, C., Balk, S. P., & Yuan, X. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.323303 · Cited by 72
Self-citationAndrogen receptor-mediated gene repression
Grosse, A., Bartsch, S., & Baniahmad, A. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.032 · Cited by 69
Hodgson, M. C., Shen, H. C., Hollenberg, A. N., & Balk, S. P. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0461 · Cited by 67
Self-citationLocke, J. A., Nelson, C. C., Adomat, H. H., Hendy, S. C., Gleave, M. E., & Guns, E. S. T. (2009) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2009.03.011 · Cited by 63
Androgen receptor levels are upregulated by Akt in prostate cancer
Ha, S., Ruoff, R., Kahoud, N., Franke, T. F., & Logan, S. K. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0204 · Cited by 60
Sox9 is required for prostate development and prostate cancer initiation
Huang, Z., Hurley, P. J., Simons, B. W., Marchionni, L., Berman, D. M., Ross, A. E., & Schaeffer, E. M. (2012) · Oncotarget · doi:10.18632/oncotarget.531 · Cited by 59
Geller, J., & Albert, J. (1987) · Urological Research · doi:10.1007/bf00254427 · Cited by 43
Bilateral Adrenalectomy for Palliative Treatment of Prostatic Cancer
Mahoney, E. M., & Harrison, J. H. (1972) · The Journal of Urology · doi:10.1016/s0022-5347(17)60911-x · Cited by 40
Alien Interacts with the Human Androgen Receptor and Inhibits Prostate Cancer Cell Growth
Moehren, U., Papaioannou, M., Reeb, C. A., Wei, H., & Baniahmad, A. (2007) · Molecular Endocrinology · doi:10.1210/me.2006-0468 · Cited by 37
Interaction between the androgen receptor and a segment of its corepressor SHP
Jouravel, N., Sablin, E. P., Arnold, L. A., Guy, R. K., & Fletterick, R. J. (2007) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444907045702 · Cited by 25
Shen, H. C., Shanmugasundaram, K., Simon, N. I., Cai, C., Wang, H., Chen, S., Balk, S. P., & Rigby, A. C. (2012) · Molecular Endocrinology · doi:10.1210/me.2012-1222 · Cited by 24
Self-citationWang, H., Xu, Y., Fang, Z., Chen, S., Balk, S. P., & Yuan, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041330 · Cited by 13
Self-citation
Cited by
AMPK activators: mechanisms of action and physiological activities
Kim, J., Yang, G., Kim, Y., Kim, J., & Ha, J. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.16 · Cited by 817
Opportunities and challenges in combination gene cancer therapy
Nastiuk, K. L., & Krolewski, J. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.005 · Cited by 85
Barfeld, S. J., East, P., Zuber, V., & Mills, I. G. (2014) · BMC Medical Genomics · doi:10.1186/s12920-014-0074-9 · Cited by 47
Metadata
- Authors
- Yuan, X., Cai, C., Chen, S., Chen, S., Yu, Z., & Balk, S. P.
- Venue
- Oncogene
- Published
- 2013-06-10
- Volume
- 33
- Issue
- 22
- Pages
- 2815-2825
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2077438659
- Cited by
- 370
- References
- 162
- FWCI
- 26.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.